A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1 mg estradiol valerate/2 mg dienogest on hot flushes in postmenopausal women
article
OA: closed
CC0
⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This study evaluated the efficacy of a continuous-combined hormone therapy containing estradiol valerate and dienogest in reducing hot flushes among postmenopausal women.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (61)
- Breast cancer and hormone-replacement therapy: the Million Women Study via openalex
- Climodien® (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints via openalex
- Climodien<sup>®</sup>(estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints via crossref
- Climodien<sup>®</sup>(estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints via openalex
- Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment. via openalex
- Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest<sup>®</sup>for continuous combined hormone replacement therapy in postmenopausal women via crossref
- Comparison of the efficacy and endometrial safety of two estradiol valerate/dienogest combinations and Kliogest<sup>®</sup>for continuous combined hormone replacement therapy in postmenopausal women via openalex
- W2525965622 via openalex
- W4285719527 via openalex
- W6682082435 via openalex
- W6715745937 via openalex
- W6836852948 via openalex
- doi:10.1016/s0378-5122(01)00254-7 via openalex
- doi:10.1016/s0025-7753(02)73435-0 via openalex
- doi:10.1016/j.amjsurg.2003.12.063 via openalex
- doi:10.1034/j.1600-0412.2003.00185.x via openalex
- doi:10.1001/jama.285.22.2891 via openalex
- doi:10.1016/s0378-5122(03)00181-6 via openalex
- doi:10.1136/bmj.298.6667.147 via openalex
- doi:10.1016/s0140-6736(03)14065-2 via openalex
- doi:10.1016/j.maturitas.2003.09.002 via openalex
- doi:10.1001/jama.288.3.321 via openalex
- doi:10.1016/j.gyobfe.2004.10.020 via openalex
- doi:10.1002/nur.4770080308 via openalex
- doi:10.1016/0002-9378(79)90288-6 via openalex
- doi:10.1016/0002-9378(79)90289-8 via openalex
- doi:10.1007/s001980170152 via openalex
- doi:10.1177/0193945902250413 via openalex
- doi:10.1177/0193945902250414 via openalex
- doi:10.1016/0378-5122(86)90022-8 via openalex
- doi:10.1001/jama.291.14.1701 via openalex
- doi:10.1080/cmt.6.1.23.30 via openalex
- doi:10.1080/13697130400001380 via openalex
- doi:10.1001/jama.289.24.3243 via openalex
- doi:10.1016/s0378-5122(03)00216-0 via openalex
- doi:10.1016/s0378-5122(03)00216-0 via crossref
- doi:10.1002/nur.4770080308 via crossref
- doi:10.1080/cmt.4.1.58.74 via crossref
- doi:10.1007/s001980170152 via crossref
- doi:10.1186/1471-2474-2-7 via crossref
- doi:10.1001/jama.285.22.2891 via crossref
- doi:10.1016/0002-9378(79)90289-8 via crossref
- doi:10.1016/0378-5122(86)90022-8 via crossref
- doi:10.1136/bmj.298.6667.147 via crossref
- doi:10.1001/jama.289.24.3243 via crossref
- doi:10.1001/jama.288.3.321 via crossref
- doi:10.1001/jama.291.14.1701 via crossref
- doi:10.1080/13697130410001713797 via crossref
- doi:10.1080/13697130400001380 via crossref
- doi:10.1016/s0378-5122(03)00181-6 via crossref
- doi:10.1016/s0378-5122(01)00254-7 via crossref
- doi:10.1177/0193945902250413 via crossref
- doi:10.1080/13697130310001651481 via crossref
- doi:10.1080/13697130410001713797 via openalex
- doi:10.1016/j.gyobfe.2004.10.020 via crossref
- doi:10.1080/13697130310001651481 via openalex
- doi:10.1080/cmt.4.1.58.74 via openalex
- doi:10.1080/713605036 via openalex
- W2149300328 via openalex
- W2412990489 via openalex
- doi:10.1186/1471-2474-2-7 via openalex
Cited by (3)
- Effectiveness, tolerability and acceptance of a low-dosed estradiol/dienogest formulation (Lafamme 1 mg/2 mg) for the treatment of menopausal complaints: a non-interventional observational study over 6 cycles of 28 days 2015
- Sequential Management with Gonadotropin-Releasing Hormone Agonist and Dienogest of Endometriosis-Associated Uterine Myoma and Adenomyosis 2012
- Effect of dienogest on estrogen-induced nitric oxide production in human umbilical vein endothelial cells and endothelium-dependent vasodilatation in postmenopausal women 2010
Source provenance
- crossref
- last seen: 2026-05-15T01:00:10.704254+00:00
- openalex
- last seen: 2026-05-11T06:37:04.871248+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK